Meloxicam Eg (Meloxicam)

Meloxicam blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that drive inflammation, pain, and fever. By limiting prostaglandin formation, the drug diminishes the inflammatory response and provides analgesic relief.

The specific dose of Meloxicam Eg is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Only a qualified health professional should set the dosing regimen.

Safety data for meloxicam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a healthcare provider after careful evaluation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meloxicam offers a longer half‑life and preferential COX‑2 inhibition, which may provide once‑daily dosing and a slightly lower risk of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or naproxen. However, individual response and safety profiles vary, so clinicians choose the agent best suited to each patient.

Meloxicam Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and sources of heat to maintain its stability and potency.

Meloxicam Eg is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals. Swallow the tablet whole; do not crush or chew.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe liver injury, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Meloxicam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulceration, severe renal or hepatic impairment, and patients who have had a recent coronary artery bypass graft. It should also be used with caution in the elderly and in patients with cardiovascular disease.